To all articles

Applications of Proteomics

Translating Proteomics Episode 12 – A New Era in Alzheimer’s Research with Sarah DeVos

Nautilus Biotechnology

Nautilus Biotechnology

November 14, 2024


Headshots of Sarah DeVos and Andreas Huhmer next to the Translating Proteomics logo

On this episode of Translating Proteomics, host Andreas Huhmer discusses advances in Alzheimer’s research with special guest and Curie Bio Drug Maker in Residence, Dr. Sarah DeVos. Their conversation focuses on:

  • The impact of molecular diagnostics on Alzheimer’s research
  • Recent Alzheimer’s drug approvals
  • The future of Alzheimer’s research

Find this episode on Apple Podcasts, Spotify, or YouTube.

Browse all episodes of Translating Proteomics.

Chapters

00:00 – Introduction

01:54 – Why Sarah began studying Alzheimer’s

03:39 – Current tools and needs for future Alzheimer’s diagnostics

09:52 – Recent drug approvals in the Alzheimer’s space and their relationship to diagnostics

14:26 – Is it possible to develop biomarkers that detect Alzheimer’s at its earliest stages?

16:36 – What is limiting the development of new Alzheimer’s biomarkers?

17:51 – The DIAN trials and learnings from studying dominantly inherited Alzheimer’s

19:33 – The genetics of Alzheimer’s

22:19 – Novel approaches to identifying and understanding Alzheimer’s pathology

25:54 – Where can proteomics advance Alzheimer’s research?

31:25 – The role of proteomics in Alzheimer’s animal models

34:33 – Sarah’s hopes for the next 10 years of Alzheimer’s research

41:39 – Outro

Resources

Dominant Inherited Alzheimer’s Network (DIAN) trials research updates

o   In the DIAN trials, researchers work with families to study various clinical and basic science aspects of dominantly inherited Alzheimer’s disease.

Amyloid plaque reducing clinical trials:

o   Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease (Haeberlein et al. 2022)

o   Donanemab in Early Symptomatic Alzheimer Disease – The TRAILBLAZER-ALZ 2 Randomized Clinical Trial (Sims et al. 2023)

o   Lecanemab in Early Alzheimer’s Disease (Van Duck et al. 2022)

Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Car (Palmqvist et al. 2024)

o   Clinical research into a new phospo-tau biomarker that can help physicians more effectively diagnose Alzheimer’s disease

Resurrecting the Mysteries of Big Tau (Fischer and Baas 2021)

o   Review covering a potentially neuro-protective form of tau called “Big tau”

Integrated Proteomics to Understand the Role of Neuritin (NRN1) as a Mediator of Cognitive Resilience to Alzheimer’s Disease (Hurst et al. 2023)

o   Paper linking the NRN1 protein to cognitive resilience in Alzheimer’s

o   Nautilus blog post about this paper

All Translating Proteomics episode links

Ep 1 – Poised for a Proteomics Breakthrough
Ep 2 – Putting Proteomics to Work
Ep 3 – Biology in Space and Time
Ep 4 – Single-protein Biomarkers Don’t Cut It
Ep 5 – Why the Dogma around Biology’s Central Dogma Is Wrong
Ep 6 – The Future of AI in Biomedicine
Ep 7 – Harnessing Proteoforms to Understand Life’s Complexity
Ep 8 – Expanding the Druggable Universe with Proteomics
Ep 9 – Are proteins a myth? With Special Guest Neil Kelleher
Ep 10 – Protein Function 201 with Kathryn Lilley
Ep 11 – Plasma Proteomics – The Dream and the Nightmare
Ep 12 – A New Era in Alzheimer’s Research with Sarah DeVos
Ep 13 – AI and Biotech – The Promise and the Pitfalls with Vijay Pande and Matt McIlwain

Share this Article

Stay up-to-date on all things Nautilus

World-class articles, delivered weekly

MORE ARTICLES

Stay up-to-date on all things Nautilus

Subscribe to our Newsletter